Brought to you by 
Hepalink takes 10% stake in ProMetic; companies sign R&D collaboration
05 Aug 2022
Executive Summary
ProMetic Life Sciences Inc. (blood purification processes and drug candidates for various diseases) and heparin manufacturer Shenzhen Hepalink Pharmaceutical Co. Ltd. have established a joint R&D collaboration involving ProMetic's protein technologies. In addition, Hepalink is taking a 10.02% stake in ProMetic for $Cdn10mm ($9.6mm).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hepalink takes 10% stake in ProMetic; companies sign R&D collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice